Renal Cell Carcinoma

MD IQ

From the Journals

IMDC model mirrors mRCC clinical outcomes

Patients with mRCC stratified into favorable- and intermediate-risk categories had better response rates and longer survival than did poor-risk...

From the Journals

Checkpoint inhibitors get to patients quickly

Within about 4 months of FDA approval of PD-1 inhibitors, the majority of patients with melanoma, NSCLC, and RCC began receiving these agents.

Feature

Company discontinues phase 3 ADAPT for mRCC

A second interim analysis of the trial comparing Rocapuldencel-T in combination with sunitinib to sunitinib monotherapy led Argos Therapeutics to...

Pages